Sarepta Wins Priority Review For Duchenne Drug Eteplirsen
This article was originally published in Scrip
Executive Summary
Shares of Sarepta Therapeutics rose 6% in after-hours trading on Aug. 25 after the company said its new drug application (NDA) for its experimental Duchenne muscular dystrophy (DMD) drug eteplirsen gained a priority review, with the FDA setting Feb. 26, 2016, as the Prescription Drug User Fee Act action date.